Cover Image
市場調查報告書

全球非血液癌症治療藥市場預測

Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics

出版商 GBI Research 商品編碼 357638
出版日期 內容資訊 英文 183 Pages
訂單完成後即時交付
價格
Back to Top
全球非血液癌症治療藥市場預測 Global Non-Hematological Cancers Market to 2021 - Strong growth driven by increased uptake of low toxicity targeted treatments and versatile biologics
出版日期: 2016年04月01日 內容資訊: 英文 183 Pages
簡介

全球非血液癌症治療藥市場的收益2014年為730億美元,2021年擴大到1,410億美元,預計2014年∼2021年以9.86%的年複合成長率成長。

本報告提供非血液癌症治療藥市場相關調查分析,主要上市產品,開發平台情形的評估,市場預測,企業分析,策略性整合等系統性資訊。

第1章 目錄

第2章 簡介

第3章 主要上市產品

  • 概要
  • Avastin (bevacizumab)
  • Herceptin (trastuzumab)
  • Alimta (pemetrexed)
  • Zytiga (abiraterone acetate)
  • Xtandi (enzalutamide)
  • Perjeta (pertuzumab)
  • Tarceva (erlotinib hydrochloride)
  • Yervoy (ipilimumab)
  • 結論

第4章 開發平台情形的評估

  • 概要
  • 開發平台開發情形
  • 開發平台的分子標的
  • 臨床實驗
  • 主要的開發中產品的評估

第5章 複數方案的市場預測

  • 綜合性的市場規模
  • 學名藥的普及
  • 收益預測:各分子標的
  • 收益、市場佔有率分析:各企業

第6章 企業分析與地位

  • 企業形勢
  • 上市、產品研發線分析

第7章 策略性整合

  • 許可證交易
  • 共同開發交易

第8章 附錄

圖表

目錄
Product Code: GBIHC405MR

Executive Summary

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis, non-hematological cancers are thought to account for 94% of global cancer prevalence. The key cancer indications of this report, namely breast, colorectal, lung and prostate cancer, constitute approximately 51% of global cancer prevalence.

The risk of cancer increases greatly in patients over the age of 65. As populations are projected to increase, with aging and increasing incidence of obesity, the prevalence of cancer as a genetic disease is only anticipated to increase, thereby acting as a driver for revenue growth.  Typically, chemotherapy has curative or palliative uses depending on whether the patient’s tumors are resectable or unresectable, respectively; however, use of chemotherapies is often reliant on performance status, which is lacking in many cancer patients.

There has been a shift towards developing targeted therapies, which by their nature have less toxicity associated with their use and as a result can be administered to greater numbers of cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope

  • Global revenues for the non-hematological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 9.86%, from $73 billion in 2014 to $141 billion in 2021.
  • What is the generic penetration?
  • Which drugs will achieve blockbuster status?
  • Overall, there are 6,484 oncology products in the pipeline, which make it the largest therapy area pipeline.
  • How does the composition of the pipeline compare with that of the existing market?
  • What mechanisms of action are most common for pipeline drugs?
  • 18 of the top 20 pharmaceutical companies will market non-hematological cancer drugs in the forecast period.
  • How is their revenue share of the non-hematological cancer market set to change?
  • What CAGR will these companies register in the forecast period?

Reasons to buy

This report will allow you to -

  • Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis.
  • Visualize the composition of the non-hematological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
  • Analyze the non-hematological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications.
  • Understand the growth in patient epidemiology and market revenues for the non-hematological cancer market globally and across the key players and product types.
  • Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various non-hematological cancers.
  • Identify commercial opportunities in the non-hematological cancer deals landscape by analyzing trends in licensing and co-development deals.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Therapy Area Introduction
  • 2.2. Symptoms
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Etiology
    • 2.3.2. Pathophysiology
    • 2.3.3. Tumor Initiation
    • 2.3.4. Enhanced Growth, Evasion of Apoptosis and Replicative Immortality
    • 2.3.5. Tumor Metabolic Shift
    • 2.3.6. Tumor Progression, Invasion and Metastasis
    • 2.3.7. Evasion of the Immune Response
    • 2.3.8. Cancer Stem Cells
  • 2.4. Co-morbidities and Complications
  • 2.5. Epidemiology Patterns-Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
    • 2.5.1. Breast Cancer
    • 2.5.2. Colorectal Cancer
    • 2.5.3. Lung Cancer
    • 2.5.4. Prostate Cancer
  • 2.6. Treatment
    • 2.6.1. Surgery and Radiation Therapy
    • 2.6.2. Chemotherapy
    • 2.6.3. Hormonal Therapies
    • 2.6.4. Targeted Therapies

3. Key Marketed Products

  • 3.1. Overview
  • 3.2. Avastin (bevacizumab)
  • 3.3. Herceptin (trastuzumab)
  • 3.4. Alimta (pemetrexed)
  • 3.5. Zytiga (abiraterone acetate)
  • 3.6. Xtandi (enzalutamide)
  • 3.7. Perjeta (pertuzumab)
  • 3.8. Tarceva (erlotinib hydrochloride)
  • 3.9. Yervoy (ipilimumab)
  • 3.10. Conclusion

4. Pipeline Landscape Assessment

  • 4.1. Overview
  • 4.2. Pipeline Development Landscape
  • 4.3. Molecular Targets in the Pipeline
  • 4.4. Clinical Trials
    • 4.4.1. Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.2. Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.3. Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.4. Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
    • 4.4.5. Conclusion
  • 4.5. Assessment of Key Pipeline Products
    • 4.5.1. Neratinib-Puma Biotechnology
    • 4.5.2. AZD-4736-AstraZeneca
    • 4.5.3. LY2835219-Eli Lilly
    • 4.5.4. LEE-011-Novartis
    • 4.5.5. JNJ-56021927-Johnson & Johnson
    • 4.5.6. Tremelimumab-AstraZeneca
    • 4.5.7. Margetuximab-Macrogenics
    • 4.5.8. Conclusion

5. Multi-scenario Market Forecast to 2021

  • 5.1. Overall Market Size
  • 5.2. Generic Penetration
  • 5.3. Revenue Forecast by Molecular Target
    • 5.3.1. Epidermal Growth Factor Receptors
    • 5.3.2. Cyclin-Dependent Kinase 4 and 6
    • 5.3.3. Programmed Cell Death Protein 1 Inhibitor
    • 5.3.4. VEGF Inhibitors
    • 5.3.5. ALK Tyrosine Kinase Receptor
    • 5.3.6. Androgen Receptor Antagonists
  • 5.4. Revenue and Market Share Analysis by Company
    • 5.4.1. Roche-To What Extent Will Newly Approved and Pipeline Product Approvals Offset Avastin's and Herceptin's Patent Expiries?
    • 5.4.2. Novartis-Markets Blockbuster Drugs, but How Much of These Revenues Are Related to Non-hematological Cancers?
    • 5.4.3. Bristol-Myers-What Does Limited Product Selection for Non-hematological Cancers Mean for Revenues?
    • 5.4.4. Pfizer-What Do Patent Expiries Mean for Pfizer?
    • 5.4.5. Astellas-Tarceva's Expiry Effects
    • 5.4.6. Amgen-Growth Despite Multiple Patent Expiries

6. Company Analysis and Positioning

  • 6.1. Company Landscape
  • 6.2. Marketed and Pipeline Portfolio Analysis

7. Strategic Consolidations

  • 7.1. Licensing Deals
    • 7.1.1. Deals by Region, Year and Value
    • 7.1.2. Deals by Stage of Development and Value
    • 7.1.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.1.4. Table for Licensing Deals Valued Above $100m
  • 7.2. Co-development Deals
    • 7.2.1. Deals by Region, Year and Value
    • 7.2.2. Deals by Stage of Development and Value
    • 7.2.3. Deals by Molecule Type, Mechanism of Action and Value
    • 7.2.4. Table for Co-development Deals Valued Above $100m

8. Appendix

  • 8.1. References
  • 8.2. Table of All Clinical Stage Pipeline Products
  • 8.3. Abbreviations
  • 8.4. Methodology
    • 8.4.1. Coverage
    • 8.4.2. Secondary Research
    • 8.4.3. Market Size and Revenue Forecasts
    • 8.4.4. Pipeline Analysis
    • 8.4.5. Competitive Landscape
  • 8.5. Contact Us
  • 8.6. Disclaimer

List of Tables

  • Table 1: Oncology, Global, Symptoms of Most Prevalent Non-hematological Cancers, 2015
  • Table 2: Complications Associated with Breast, Colorectal, Lung and Prostate Cancers
  • Table 3: Oncology, Global, Epidemiology of Most Prevalent Non-hematological Cancers, 2015
  • Table 4: Optimal and Actual Radiation Therapy Usage Rates, US, 1995-2000
  • Table 5: Optimal and Actual Chemotherapy Usage Rates, Australia, 2010
  • Table 6: Oncology Therapeutics Market, Global, Approved Indications for Avastin, 2015
  • Table 7: Oncology Therapeutics Market, Global, Approved Indications for Herceptin, 2015
  • Table 8: Oncology Therapeutics Market, Global, Approved Indications for Alimta, 2015
  • Table 9: Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2015
  • Table 10: Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2015
  • Table 11: Oncology Therapeutics Market, Global, Approved Indications for Perjeta, 2015
  • Table 12: Oncology Therapeutics Market, Global, Approved Indications for Tarceva, 2015
  • Table 13: Oncology Therapeutics Market, Global, Approved Indications for Yervoy, 2015
  • Table 14: Oncology, Global, Market Size ($bn), 2014-2021
  • Table 15: Oncology, Global, Usage of Generics Across Key Indications, 2016
  • Table 16: Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2014-2021
  • Table 17: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
  • Table 18: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016
  • Table 19: Oncology, Global, All Clinical Stage Pipeline Products, 2016
  • Table 20: Abbreviations

List of Figures

  • Figure 1: Oncology, Major Markets, Treatment Usage Patterns for Breast Cancer, Patients ('000), 2014-2021
  • Figure 2: Oncology, Major Markets, Treatment Usage Patterns for Colorectal Cancer, Patients ('000), 2014-2021
  • Figure 3: Oncology, Major Markets, Treatment Usage Patterns for Lung Cancer, Patients ('000), 2014-2021
  • Figure 4: Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients ('000), 2014-2021
  • Figure 5: Non-hematological Cancer, Global, Key Marketed Products and Approved Indications, 2015
  • Figure 6: Oncology Therapeutics Market, Global, Annual Revenues for Avastin ($bn), 2006-2021
  • Figure 7: Oncology Therapeutics Market, Global, Annual Revenues for Herceptin ($bn), 2006-2021
  • Figure 8: Oncology Therapeutics Market, Global, Annual Revenues for Alimta ($bn), 2006-2021
  • Figure 9: Oncology Therapeutics Market, Global, Annual Revenues for Zytiga ($bn), 2011-2021
  • Figure 10: Oncology Therapeutics Market, Global, Annual Revenues for Xtandi ($bn), 2012-2021
  • Figure 11: Oncology Therapeutics Market, Global, Annual Revenues for Perjeta ($bn), 2012-2021
  • Figure 12: Oncology Therapeutics Market, Global, Annual Revenues for Tarceva ($bn), 2006-2021
  • Figure 13: Oncology Therapeutics Market, Global, Annual Revenues for Yervoy ($bn), 2011-2021
  • Figure 14: Oncology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
  • Figure 15: Oncology Therapeutics Market, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2016
  • Figure 16: Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016
  • Figure 17: Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016
  • Figure 18: Oncology Therapeutics Market, Global, Pipeline for Oncology by Molecular Target, 2016
  • Figure 19: Oncology Therapeutics Market, Global, Pipeline by Mechanism of Action and Stage of Development, 2016
  • Figure 20: Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016
  • Figure 21: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
  • Figure 22: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
  • Figure 23: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
  • Figure 24: Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
  • Figure 25: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (months), 2006-2016
  • Figure 26: Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
  • Figure 27: Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
  • Figure 28: Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
  • Figure 29: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006-2016
  • Figure 30: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 31: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 32: Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 33: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
  • Figure 34: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
  • Figure 35: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
  • Figure 36: Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
  • Figure 37: Oncology Therapeutics Market, Global, Revenue Forecast for neratinib ($m), 2014-2021
  • Figure 38: Oncology Therapeutics Market, Global, Revenue Forecast for AZD-4736 ($m), 2014-2021
  • Figure 39: Oncology Therapeutics Market, Global, Revenue Forecast for LY2835219 ($m), 2014-2021
  • Figure 40: Oncology Therapeutics Market, Global, Revenue Forecast for LEE-011 ($m), 2014-2021
  • Figure 41: Oncology Therapeutics Market, Global, Revenue Forecast for JNJ-56021927 ($m), 2014-2021
  • Figure 42: Oncology Therapeutics Market, Global, Revenue Forecast for Tremelimumab ($m), 2014-2021
  • Figure 43: Oncology Therapeutics Market, Global, Revenue Forecast for Margetuximab ($m), 2014-2021
  • Figure 44: Oncology, Global, Market Size ($bn), 2014-2021
  • Figure 45: Oncology, Global, Annual Revenue Forecast for Key Products ($bn), 2014-2021
  • Figure 46: Oncology, Global, Annual Revenue Forecast for Epidermal Growth Factor Receptors ($bn), 2014-2021
  • Figure 47: Oncology, Global, Annual Revenue Forecast for Cyclin-Dependent Kinase 4 and 6 ($bn), 2014-2021
  • Figure 48: Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1 ($bn), 2014-2021
  • Figure 49: Oncology, Global, Annual Revenue Forecast for VEGF Inhibitors ($bn), 2014-2021
  • Figure 50: Oncology, Global, Annual Revenue Forecast for ALK Tyrosine Kinase Receptor ($bn), 2014-2021
  • Figure 51: Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2014-2021
  • Figure 52: Oncology Therapeutics Market, Global, Forecast Market Share by Company (%), 2014-2021
  • Figure 53: Oncology, Global, Companies by Compound Annual Growth Rate (%), 2014-2021
  • Figure 54: Oncology, Global, Revenues by Product Type, 2014-2021
  • Figure 55: Oncology, Global, Roche Oncology Annual Revenue Forecast ($bn), 2014-2021
  • Figure 56: Oncology, Global, Novartis AG Annual Revenue Forecast ($m), 2014-2021
  • Figure 57: Oncology, Global, Bristol-Myers Annual Revenue Forecast ($m), 2014-2021
  • Figure 58: Oncology, Global, Pfizer Annual Revenue Forecast ($m), 2014-2021
  • Figure 59: Oncology, Astellas Annual Revenue Forecast ($m), 2014-2021
  • Figure 60: Oncology, Amgen Annual Revenue Forecast ($m), 2014-2021
  • Figure 61: Oncology, Global, Companies by Type, 2014-2021
  • Figure 62: Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Non-Haematological Cancer Specialization, 2014-2021
  • Figure 63: Oncology, Global, Proportion of Total Company Revenue Attributed to Non-Haematological Cancer, 2014-2021
  • Figure 64: Oncology, Global, Licensing Deals, 2006-2016
  • Figure 65: Oncology, Global, Licensing Deals by Indication and Value, 2006-2016
  • Figure 66: Oncology, Global, Licensing Deals, 2006-2016
  • Figure 67: Oncology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006-2016
  • Figure 68: Oncology, Global, Co-development Deals, 2006-2016
  • Figure 69: Oncology, Global, Co-development Deals by Indication and Value, 2006-2016
  • Figure 70: Oncology, Global, Co-development Deals, 2006-2016
  • Figure 71: Oncology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006-2016
Back to Top